BIO-TECHNE Corp — Director's Dealing 2021

Nov 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2021-11-19

Reporting Person: Kelderman Kim (Pres. Diagnostics & Genom)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-19	Common Stock	M	500	$150.78	Acquired	500	Direct
2021-11-19	Common Stock	S	100	$503.76	Disposed	400	Direct
2021-11-19	Common Stock	S	400	$505.7825	Disposed	0	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-19	Stock Option (Right to Buy)	$150.78	M	500	Disposed	2025-05-01	Common Stock (500)	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$150.7800	2025-05-01	Common Stock (7348)	7348	Direct
Stock Option (Right to Buy)	$177.3200	2025-08-08	Common Stock (12044)	12044	Direct
Stock Option (Right to Buy)	$177.3200	2025-08-08	Common Stock (9033)	9033	Direct
Restricted Stock Units	$		Common Stock (2363)	2363	Direct
Stock Option (Right to Buy)	$190.4100	2026-08-07	Common Stock (11961)	11961	Direct
Stock Option (Right to Buy)	$190.4100	2026-08-07	Common Stock (15948)	15948	Direct
Restricted Stock Units	$		Common Stock (2015)	2015	Direct
Stock Option (Right to Buy)	$267.8700	2027-08-05	Common Stock (8991)	8991	Direct
Stock Option (Right to Buy)	$267.8700	2027-08-05	Common Stock (11988)	11988	Direct
Stock Option (Right to Buy)	$267.8700	2027-08-05	Common Stock (8325)	8325	Direct
Stock Option (Right to Buy)	$267.8700	2027-08-05	Common Stock (8325)	8325	Direct
Restricted Stock Units	$		Common Stock (1245)	1245	Direct
Stock Option (Right to Buy)	$481.8200	2028-08-06	Common Stock (4864)	4864	Direct
Stock Option (Right to Buy)	$481.8200	2028-08-06	Common stock (6486)	6486	Direct

Footnotes

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $505.62 to $506.17, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F2: Options to purchase 663 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.

F3: Options to purchase 1,837 shares vest on each of 5/1/2019, 5/1/2020, 5/1/2021 and 5/1/2022.

F4: Options to purchase 3,011 shares vest on each of 8/8/2019, 8/8/2020, 8/8/2021 and 8/8/2022.

F5: Fully exercisable.

F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.

F7: Vests in full or in part on 8/7/2022 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F8: Options to purchase 3,987 shares vest on each of 8/7/2020, 8/7/2021, 8/7/2022 and 8/7/2023.

F9: Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F10: Options to purchase 2,997 shares vest on each of 8/5/2021, 8/5/2022, 8/5/2023 and 8/5/2024.

F11: Options to purchase 2,775 shares vest on each of 8/5/2021, 8/5/2022 and 8/5/2023.

F12: Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.

F13: Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

F14: Options to purchase 1,621 shares vest on each of 8/6/2022 and 8/6/2023 and options to purchase 1,622 shares vest on each of 8/6/2024 and 8/6/2025.